Healy I. James's most recent trade in Y-Mabs Therapeutics Inc was a trade of 33,450 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Y-Mabs Therapeutics Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 33,450 | 33,450 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 25,080 | 56,683 (0%) | 0% | 0 | Common Stock | |
| Rapport Therapeutics Inc. | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 21,850 | 21,850 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc. | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2025 | 142 | 46,260 (0%) | 0% | - | Common Stock | |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 114 | 46,118 (0%) | 0% | - | Common Stock | |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2024 | 153 | 46,004 (0%) | 0% | - | Common Stock | |
| BioAge Labs Inc. | James I. Healy | Director | 25 Sep 2024 | 7,310,796 | 0 | - | - | Series D Preferred Stock | ||
| BioAge Labs Inc. | James I. Healy | Director | 25 Sep 2024 | 1,638,236 | 1,638,236 | - | - | Common Stock | ||
| BioAge Labs Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 25 Sep 2024 | 588,888 | 2,227,124 | - | 18 | 10,599,984 | Common Stock |
| BioAge Labs Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 25 Sep 2024 | 26,497 | 26,497 | - | 18 | 476,946 | Common Stock |
| BioAge Labs Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 25 Sep 2024 | 21,814 | 21,814 | - | 18 | 392,652 | Common Stock |
| BioAge Labs Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 25 Sep 2024 | 18,353 | 18,353 | - | 18 | 330,354 | Common Stock |
| BioAge Labs Inc. | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 25 Sep 2024 | 11,113 | 11,113 | - | 18 | 200,034 | Common Stock |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2024 | 177 | 45,851 (0%) | 0% | - | Common Stock | |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 25.02 per share. | 01 Jul 2024 | 4,878 | 30,366 | - | 25.0 | 122,026 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 25.02 per share. | 01 Jul 2024 | 4,661 | 38,226 | - | 25.0 | 116,598 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 25.02 per share. | 01 Jul 2024 | 4,544 | 37,102 | - | 25.0 | 113,671 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 24.21 per share. | 01 Jul 2024 | 3,828 | 25,488 | - | 24.2 | 92,684 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 23.08 per share. | 01 Jul 2024 | 3,799 | 21,660 | - | 23.1 | 87,664 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 24.21 per share. | 01 Jul 2024 | 3,657 | 33,565 | - | 24.2 | 88,543 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 23.08 per share. | 01 Jul 2024 | 3,630 | 29,908 | - | 23.1 | 83,764 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 24.21 per share. | 01 Jul 2024 | 3,565 | 32,558 | - | 24.2 | 86,316 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 23.08 per share. | 01 Jul 2024 | 3,538 | 28,993 | - | 23.1 | 81,641 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 26.05 per share. | 01 Jul 2024 | 2,748 | 33,114 | - | 26.1 | 71,599 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 26.06 per share. | 01 Jul 2024 | 2,625 | 40,851 | - | 26.1 | 68,395 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 26.06 per share. | 01 Jul 2024 | 2,559 | 39,661 | - | 26.1 | 66,675 | Common Stock |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2024 | 2,964 | 45,674 (0%) | 0% | - | Common Stock | |
| Bolt Biotherapeutics Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Y-Mabs Therapeutics Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 14,545 | 14,545 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 3,495 | 31,603 (0%) | 0% | 0 | Common Stock | |
| Rapport Therapeutics Inc. | James I. Healy | Director | 10 Jun 2024 | 11,924,138 | 0 | - | - | Series B Preferred Stock | ||
| Rapport Therapeutics Inc. | James I. Healy | Director | 10 Jun 2024 | 1,392,738 | 1,392,738 | - | 0 | Common Stock | ||
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 10 Jun 2024 | 470,589 | 1,863,327 | - | 17 | 8,000,013 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 10 Jun 2024 | 26,278 | 26,278 | - | 17 | 446,726 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 10 Jun 2024 | 25,455 | 25,455 | - | 17 | 432,735 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 10 Jun 2024 | 18,641 | 18,641 | - | 17 | 316,897 | Common Stock |
| Rapport Therapeutics Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 10 Jun 2024 | 17,861 | 17,861 | - | 17 | 303,637 | Common Stock |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2024 | 210 | 42,710 (0%) | 0% | - | Common Stock | |
| ArriVent BioPharma Inc. | James I. Healy | Director | 30 Jan 2024 | 1,252,308 | 1,252,308 | - | - | Common Stock | ||
| ArriVent BioPharma Inc. | James I. Healy | Director | 30 Jan 2024 | 1,252,308 | 0 | - | - | Series B Preferred Stock | ||
| ArriVent BioPharma Inc. | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 30 Jan 2024 | 444,444 | 1,696,752 | - | 18 | 7,999,992 | Common Stock |
| Natera Inc | Healy I. James | Director | Grant, award, or other acquisition of securities at price $ 63.79 per share. | 26 Jan 2024 | 264 | 42,500 (0%) | 0% | 63.8 | 16,841 | Common Stock |
| Natera Inc | Healy James I. | Director | Sale of securities on an exchange or to another person at price $ 58.75 per share. | 13 Dec 2023 | 644,000 | 0 (0%) | 0% | 58.8 | 37,835,000 | Common Stock |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 48.48 per share. | 28 Jul 2023 | 328 | 41,840 (0%) | 0% | 48.5 | 15,901 | Common Stock |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 4,255 | 4,255 | - | - | Stock Option (right to buy) | |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 2,750 | 41,512 (0%) | 0% | - | Common Stock | |
| Karuna Therapeutics Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 1,904 | 1,904 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 990 | 33,490 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | James I. Healy | Director | Other type of transaction at price $ 0.00 per share. | 14 Jun 2023 | 400,000 | 1,372,441 (5%) | 1% | 0 | Common Stock | |
| Karuna Therapeutics Inc | James I. Healy | Director | Other type of transaction at price $ 0.00 per share. | 14 Jun 2023 | 8,025 | 8,025 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | James I. Healy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2023 | 3,534 | 38,762 (0%) | 0% | - | Common Stock | |
| Natera Inc | James I. Healy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2023 | 3,534 | 0 | - | - | Restricted Stock Unit | |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 54.73 per share. | 14 Apr 2023 | 285 | 35,228 (0%) | 0% | 54.7 | 15,598 | Common Stock |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 40.01 per share. | 13 Jan 2023 | 390 | 34,943 (0%) | 0% | 40.0 | 15,604 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Other type of transaction at price $ 0.00 per share. | 12 Jan 2023 | 300,000 | 1,772,441 (6%) | 1% | 0 | Common Stock | |
| Karuna Therapeutics Inc | James I. Healy | Director | Sale of securities on an exchange or to another person at price $ 199.90 per share. | 12 Jan 2023 | 6,027 | 0 (0%) | 0% | 199.9 | 1,204,771 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Other type of transaction at price $ 0.00 per share. | 12 Jan 2023 | 6,027 | 6,027 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | James I. Healy | Director | Sale of securities on an exchange or to another person at price $ 37.71 per share. | 16 Nov 2022 | 2,400 | 0 (0%) | 0% | 37.7 | 90,498 | Common Stock |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 45.42 per share. | 14 Oct 2022 | 344 | 34,553 (0%) | 0% | 45.4 | 15,624 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 05 Aug 2022 | 32,500 | 32,500 (0%) | 0% | 16 | 520,000 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 32,500 | 0 | - | - | Option (right to buy) | |
| Y-Mabs Therapeutics Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2022 | 16,000 | 16,000 | - | - | Non-Employee Stock Option (right to buy) | |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2022 | 430 | 430 | - | - | Restricted Stock Unit | |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 122.27 per share. | 29 Jun 2022 | 48,062 | 2,048,280 (7%) | 0% | 122.3 | 5,876,541 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 121.99 per share. | 29 Jun 2022 | 27,777 | 1,980,218 (7%) | 0% | 122.0 | 3,388,516 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 123.39 per share. | 29 Jun 2022 | 24,161 | 2,072,441 (7%) | 0% | 123.4 | 2,981,226 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 125.00 per share. | 29 Jun 2022 | 9,129 | 2,000,218 (7%) | 0% | 125 | 1,141,125 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 124.73 per share. | 29 Jun 2022 | 6,832 | 1,991,089 (7%) | 0% | 124.7 | 852,155 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 122.95 per share. | 29 Jun 2022 | 4,039 | 1,984,257 (7%) | 0% | 122.9 | 496,595 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 5,000 | 5,000 | - | - | Option (right to buy) | |
| Bolt Biotherapeutics Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2022 | 7,068 | 7,068 | - | - | Stock Option (right to buy) | |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2022 | 3,534 | 3,534 | - | - | Restricted Stock Unit | |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 129.38 per share. | 01 Apr 2022 | 47 | 683 (0%) | 0% | 129.4 | 6,081 | Common Stock |
| Bolt Biotherapeutics Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 27,000 | 27,000 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | James I. Healy | Director | Sale of securities on an exchange or to another person at price $ 16.12 per share. | 27 Sep 2021 | 286,076 | 0 (0%) | 0% | 16.1 | 4,611,545 | Common Stock, $0.0001 par value |
| Coherus Biosciences Inc | James I. Healy | Director | Sale of securities on an exchange or to another person at price $ 18.06 per share. | 27 Sep 2021 | 100,150 | 334,405 (0%) | 0% | 18.1 | 1,808,709 | Common Stock, $0.0001 par value |
| Coherus Biosciences Inc | James I. Healy | Director | Sale of securities on an exchange or to another person at price $ 17.17 per share. | 27 Sep 2021 | 48,329 | 286,076 (0%) | 0% | 17.2 | 829,809 | Common Stock, $0.0001 par value |
| Natera Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 113.00 per share. | 22 Jul 2021 | 2,400 | 2,400 (0%) | 0% | 113 | 271,200 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 117.80 per share. | 02 Jul 2021 | 636 | 636 (0%) | 0% | 117.8 | 74,923 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 8,500 | 8,500 | - | - | Option (right to buy) | |
| Natera Inc | James I. Healy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 2,856 | 0 | - | - | Restricted Stock Unit | |
| Natera Inc | James I. Healy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 2,856 | 32,472 (0%) | 0% | - | Common Stock | |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 2,614 | 2,614 | - | - | Stock Option (right to buy) | |
| Natera Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 1,307 | 1,307 | - | - | Restricted Stock Unit | |
| Bolt Biotherapeutics Inc | James I. Healy | Director | 09 Feb 2021 | 1,200,228 | 0 | - | - | Series C-2 Preferred Stock | ||
| Bolt Biotherapeutics Inc | James I. Healy | Director | 09 Feb 2021 | 1,200,228 | 2,304,437 | - | - | Common Stock | ||
| Bolt Biotherapeutics Inc | James I. Healy | Director | 09 Feb 2021 | 1,104,209 | 0 | - | - | Series C-1 Preferred Stock | ||
| Bolt Biotherapeutics Inc | James I. Healy | Director | 09 Feb 2021 | 1,104,209 | 1,104,209 | - | - | Common Stock | ||
| Bolt Biotherapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 20.00 per share. | 09 Feb 2021 | 450,000 | 2,754,437 | - | 20 | 9,000,000 | Common Stock |
| Coherus Biosciences Inc | James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | James I. Healy | Director | Other type of transaction at price $ 0.00 per share. | 29 Sep 2020 | 950,000 | 0 (0%) | 1% | 0 | Common Stock, $0.0001 par value | |
| Coherus Biosciences Inc | James I. Healy | Director | Other type of transaction at price $ 0.00 per share. | 29 Sep 2020 | 213,546 | 434,555 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 73.75 per share. | 09 Sep 2020 | 4,557 | 1,952,441 (7%) | 0% | 73.8 | 336,079 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 71.30 per share. | 04 Sep 2020 | 45,317 | 1,932,589 (7%) | 0% | 71.3 | 3,231,102 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 73.59 per share. | 04 Sep 2020 | 8,330 | 1,947,380 (7%) | 0% | 73.6 | 613,005 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 72.73 per share. | 04 Sep 2020 | 6,461 | 1,939,050 (7%) | 0% | 72.7 | 469,909 | Common Stock |
| Karuna Therapeutics Inc | James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 70.12 per share. | 04 Sep 2020 | 1,670 | 1,887,272 (7%) | 0% | 70.1 | 117,100 | Common Stock |